Abstract
This study is designed to assess the toxicity and therapeutic effectiveness of concurrent gemcitabine and radiotherapy in patients with unresectable pancreatic cancer. Concurrent gemcitabine (400 mg/m2/wk) in six weekly cycles starting on d 1 of radiotherapy (50.4 Gy; 1.8 Gy/fraction/d; 5 d/wk) was prescribed on 22 patients with locally advanced pancreatic cancer. Patients were analyzed with regard to radiological response on computerized tomography, overall survival, and toxicity. Twelve (55%) patients completed the prescription of six gemcitabine cycles and 50.4 Gy radiotherapy; while 10 (45%) received one to five cycles of gemcitabine owing to neutropenia. All patients experienced abdominal discomfort during treatment and three patients required medical intervention. Other toxicities reported were nausea in 13 patients (60%), grade 3 vomiting in 3 (14%). Radiological response evaluations were as follows: complete, 2 (9%); partial, 9 (41%); stable, 7 (32 %); and progressive, 4 (18 %). Median survival was 8.7 mo. Combination of weekly gemcitabine (400 mg/m2) and radiotherapy provided response in 50% of the patients but was associated with severe toxicity resulting in incomplete delivery of the planned chemotherapy.
Similar content being viewed by others
References
Evans DB, Abbruzzese JL, Willet CG: Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA (eds).Cancer: principles and practice of oncology. 6th ed. Lippincott-Raven: Philadelphia, 2001, pp 1054–1087.
Moertel CG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5 fluorouracil), and high dose radiation + 5 fluorouracil.Cancer 1981;48:1705–1710.
Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone.J Natl Cancer Inst 1988;80(10):751–755.
Epelbaum R, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 2002;81: 138–143.
Miller AB, Hoogstraten B, Straquet M. Reporting results of cancer treatment.Cancer 1981;147:207–214.
McCracken JD, et al. 5-Fluorouracil, methylCCNU, and radiotherapy with or without testolactone for localized adenocarcinomas of the exocrine pancreas. A Southwest Oncology Group Study.Cancer 1980;46:1518–1522.
The Gastrointestinal Tumor Study Group. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma.Cancer 1985;56:2563–2568.
Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewash DS. Radiosensitization of pancreatic cancer cells by 2,2-difluoro-2-deoxycytidine. Int J Radiat Oncol Biol Phys 1996;54(4): 867–872.
Milas L, et al. Enhancement of tumor radioresponse in vivo by gemcitabine.Cancer Res 1999;59:107–114.
McGinn C, et al. A phase I study of gemcitabine in combination with radiation therapy in patients with localized, unresectable pancreatic cancer. (Abstract 283a) Proc Am Soc Clin Oncol 1998;17:264.
Wolff RA, et al. Phase I trial of gemcitabine combined with radiation for treatment of locally advanced pancreatic adenocarcinoma.Clin Cancer Res 2001 ;7:2246–2253.
Crane CH, et al. Toxicity and efficiacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.Int J Pancreatol 2001;29(1):9–18.
Yavuz AA, Aydin F, Yavuz MN, Ilis E, Ozdemir F.. Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.Int J Radiat Oncol Biol Phys 2001;51(4): 974–981.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cengiz, M., Zorlu, F., Yalcin, S. et al. Concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Med Oncol 24, 239–243 (2007). https://doi.org/10.1007/BF02698046
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02698046